Kilitch Drugs Reports Strong Sales Growth Amid Management Efficiency Concerns in December 2024
Kilitch Drugs (India) has recently adjusted its evaluation, showcasing an 18.33% growth in net sales for the quarter ending December 2024, reaching Rs 56.17 crore. The profit after tax also saw a significant rise of 44.8%, despite challenges in management efficiency and a low debt-to-equity ratio.
Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation adjustment reflecting its current financial standing. The company reported a notable growth in net sales of 18.33% for the quarter ending December 2024, achieving a record high of Rs 56.17 crore. Additionally, the profit after tax (PAT) for the quarter reached Rs 5.96 crore, marking a significant increase of 44.8%. Despite these positive indicators, the company has faced challenges with management efficiency, as evidenced by a return on equity (ROE) of 5.61%. This suggests a lower profitability relative to shareholders' funds. Furthermore, Kilitch Drugs has maintained a low debt-to-equity ratio, indicating a conservative approach to leverage.
While the stock has generated negative returns of -22.39% over the past year, its profits have increased by 33.9%. The stock is currently trading at a discount compared to its historical valuations, which may reflect market sentiment.
For those interested in tracking the evolving financial landscape of Kilitch Drugs (India), Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
